Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493789 · ClinicalTrials.gov registry record · Phase 1
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03493789: Completed Phase 1 study, sponsored by Emory University.
NCT03493789 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03493789, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
Primary Outcome
Metabolic tumor volumes across the treatment continuum, i.e. pre-treatment, before second fraction and before the last fraction of treatment, will be compared. The observed % change from baseline will be calculated at all time points for all 15 patients and for every tumor treated with SBRT.
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-13 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 1 |
What the finished NCT03493789 record still lists
NCT03493789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT03493789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03493789 about?
NCT03493789 is a clinical study titled "Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy". This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the stan...
What is the current status of trial NCT03493789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-04-13. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03493789?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Positron Emission Tomography (PET) (PROCEDURE), Fludeoxyglucose F-18 (DRUG).
Who is sponsoring clinical trial NCT03493789?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03493789's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI